MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2013-2023

  Di Fiore, Ricardo ^a   Drago Ferrante, Rosa ^a   Pentimali, Francesca ^b   Di Marzo, Domenico ^b   Forte, Iris Maria ^b   D'anneo, Antonella ^a   Carlisi, Daniela ^a   De Blasio, Anna ^a   Giuliano, Michela ^a   Tesoriere, Giovani ^c   Giordano, Antonio ^b,c,d   Vento, Renza ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

3AB OS cells; Cancer stem cells; MicroRNA; MicroRNA 29b 1; Multidrug resistance; Osteosarcoma

Indexed keywords

CD133 ANTIGEN; MICRORNA 29B; MICRORNA 29B 1; MYC PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; UNCLASSIFIED DRUG; MICRORNA; MIRN29 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; GROWTH REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; STABLE TRANSFECTION; BIOSYNTHESIS; BONE TUMOR; CELL MOTION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA;

EID: 84954358750     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2618     Document Type: Article

References (54)

1. Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13, 2009.
2. Gorlick R and Khanna C: Osteosarcoma. J Bone Miner Res 25: 683-691, 2010.
3. Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev 28: 247-263, 2009.
4. Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085, 2006.
5. Clevers H: The cancer stem cell: Premises, promises and challenges. Nat Med 17: 313-319, 2011.
6. Li L and Neaves WB: Normal stem cells and cancer stem cells: The niche matters. Cancer Res 66: 4553-4557, 2006.
7. Maitland NJ and Collins AT: Prostate cancer stem cells: A new target for therapy. J Clin Oncol 26: 2862-2870, 2008.
8. Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G and Vento R: Identification and expansion of human osteosarcoma-cancerstem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 219: 301-313, 2009.
9. Di Fiore R, Drago-Ferrante R, D'Anneo A, De Blasio A, Santulli A, Messina C, Carlisi D, Tesoriere G and Vento R: Differentiation of human osteosarcoma 3AB-OS stem-like cells in derivatives of the three primary germ layers as an useful in vitro model to develop several purposes. Stem Cell Discov 3: 188-201, 2013.
10. Di Fiore R, Guercio A, Puleio R, Di Marco P, Drago-Ferrante R, D'Anneo A, De Blasio A, Carlisi D, Di Bella S, Pentimalli F, Forte IM, Giordano A, Tesoriere G and Vento R: Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts. J Cell Biochem 113: 3380-3392, 2012.
11. Di Fiore R, Fanale D, Drago-Ferrante R, Chiaradonna F, Giuliano M, De Blasio A, Amodeo V, Corsini LR, Bazan V, Tesoriere G, Vento R and Russo A: Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness. J Cell Physiol 228: 1189-1201, 2013.
12. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
13. Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
14. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
15. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC and Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
16. Hatfield S and Ruohola-Baker H: MicroRNA and stem cell function. Cell Tissue Res 331: 57-66, 2008.
17. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is regulated by the microRNA pathway. Nature 435: 974-978, 2005.
18. Zhang B, Pan X and Anderson TA: MicroRNA: A new player in stem cells. J Cell Physiol 209: 266-269, 2006.
19. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R and Hannon GJ: A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 21: 3238-3243, 2007.
20. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J and Song E: Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
21. Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 204: 138-146, 2011.
22. Lulla RR, Costa FF, Bischof JM, Chou PM, de F Bonaldo M, Vanin EF and Soares MB: Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011: 732690, 2011.
23. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB and Aqeilan RI: MiRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 72: 1865-1877, 2012.
24. Zhang W, Qian JX, Yi HL, Yang ZD, Wang CF, Chen JY, Wei XZ, Fu Q and Ma H: The microRNA-29 plays a central role in osteosarcoma pathogenesis and progression. Mol Biol (Mosk) 46: 622-627, 2012.
25. Di Fiore R, Marcatti M, Drago-Ferrante R, D'Anneo A, Giuliano M, Carlisi D, De Blasio A, Querques F, Pastore L, Tesoriere G and Vento R: Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells. Bone 60: 198-212, 2014.
26. Gawrychowski J, Lackowska B and Gabriel A: Prognosis of the surgical treatment of patients with non-small cell lung cancer (NSCLC) -relation to DNA ploidy. Eur J Cardiothorac Surg 23: 870-877, 2003.
27. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403, 2006.
28. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219, 2005.
29. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25: 2022-2030, 2011.
30. Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, Yang T and Liu W: CD133 expression in osteosarcoma and derivation of CD133+ cells. Mol Med Rep 7: 577-584, 2013.
31. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS and Carbone M: Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63: 37-50, 1996.
32. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA and Cleton-Jansen AM: Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 51: 696-706, 2012.
33. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O and Meza-Zepeda LA: Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One 7: E48262, 2012.
34. Pösl M, Amling M, Werner M, Bäsler I, Salzer-Kuntschik M, Winkler K and Delling G: Osteosarcoma -apoptosis and proliferation. Study of bcl-2 expression. Pathologe 15: 337-344, 1994.
35. Wu X, Cai ZD, Lou LM and Zhu YB: Expression of p53, BCL-2, and apoptotic index in human osteosarcoma and their correlation with prognosis of patients. Cancer Epidemiol 36: 212-216, 2012.
36. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol 17: 118-126, 2007.
37. Wang Y, Zhang X, Li H, Yu J and Ren X: The role of miRNA-29 family in cancer. Eur J Cell Biol 92: 123-128, 2013.
38. Ogawa H, Ishiguro K, Gaubatz S, Livingston DM and Nakatani Y: A complex with chromatin modifiers that occupies E2F-and Myc-responsive genes in G0 cells. Science 296: 1132-1136, 2002.
39. Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, Wang Y, Luo M, Zhao H, Dong L, Song W, Wang F, Wang W, Zhang J and Yu J: Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis 35: 497-506, 2014.
40. Li L, Sarver AL, Alamgir S and Subramanian S: Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 92: 571-583, 2012.
41. Dimova DK and Dyson NJ: The E2F transcriptional network: Old acquaintances with new faces. Oncogene 24: 2810-2826, 2005.
42. Chen C and Wells AD: Comparative analysis of E2F family member oncogenic activity. PLoS One 2: E912, 2007.
43. Vidal A and Koff A: Cell-cycle inhibitors: Three families united by a common cause. Gene 247: 1-15, 2000.
44. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza BA, Meyers PA and Gorlick R: 2004. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res 64: 2734-2739, 2004.
45. Shiratsuchi H, Nakashima T, Hirakawa N, Toh S, Nakagawa T, Saito T, Tsuneyoshi M and Komune S: Beta-Catenin nuclear accumulation in head and neck mucoepidermoid carcinoma: Its role in cyclin D1 overexpression and tumor progression. Head Neck 29: 577-584, 2007.
46. Ohira M, Oba S, Nakamura Y, Hirata T, Ishii S and Nakagawara A: A review of DNA microarray analysis of human neuroblastomas. Cancer Lett 228: 5-11, 2005.
47. Kessler JD, Hasegawa H, Brun SN, Emmenegger BA, Yang ZJ, Dutton JW, Wang F and Wechsler-Reya RJ: N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev 23: 157-170, 2009.
48. Okita K, Ichisaka T and Yamanaka S: Generation of germlinecompetent induced pluripotent stem cells. Nature 448: 313-317, 2007.
49. Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006.
50. Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406, 2008.
51. de Almagro MC and Vucic D: The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 34: 200-211, 2012.
52. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845, 2010.
53. Ru P, Steele R, Newhall P, Phillips NJ, Toth K and Ray RB: MiRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 11: 1166-1173, 2012.
54. Gebeshuber CA, Zatloukal K and Martinez J: MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10: 400-405, 2009.